Across a large variety of Mendelian disorders, ~50-75% of patients do not receive a 45 genetic diagnosis by whole exome sequencing indicative of underlying disease-causing 46 variants in non-coding regions. In contrast, whole genome sequencing facilitates the 47 discovery of all genetic variants, but their sizeable number, coupled with a poor 48 understanding of the non-coding genome, makes their prioritization challenging. Here, we 49 demonstrate the power of transcriptome sequencing to provide a confirmed genetic 50 diagnosis for 10% (5 of 48) of undiagnosed mitochondrial disease patients and identify 51 strong candidate genes for patients remaining without diagnosis. We found a median of 1 52 aberrantly expressed gene, 5 aberrant splicing events, and 6 mono-allelically expressed 53 rare variants in patient-derived fibroblasts and established disease-causing roles for each 54 kind. Private exons often arose from sites that are weakly spliced in other individuals, 55
heterozygous variants within one gene as cause of TAR syndrome, where one allele is deleted 88 and the other harbors a non-coding variant that reduces expression 14 . Mono-allelic expression 89
can also have epigenetic causes such as X-chromosome inactivation or imprinting on autosomal 90 genes, possibly by random choice 15, 16 . Third, splicing of a gene can be affected. Aberrant 91 splicing has long been recognized as a major cause of Mendelian disorders (reviewed in ref. 17-92 19 ). However, the prediction of splicing defects from genetic sequence is difficult because 93 splicing involves a complex set of cis-regulatory elements that are not yet fully understood. 94 Some of them can be deeply located in intronic sequences 20 and are thus not covered by WES. 95 Hence, direct probing of splice isoforms by RNA-seq is important, and has led to the discovery 96 of multiple splicing defects based on single gene studies: skipping of multiple exons (exon 45-97 55) 21 and creation of a new exon by a deep intronic variant in DMD 22 , intron retention in LMNA 98 caused by a 5' splice site variant 23 , and skipping of exon 7 in SMN1 caused by a variant in a 99 splicing factor binding site 24 . Altogether, RNA-seq promises to be an important complementary 100 tool to facilitate molecular diagnosis of rare genetic disorders. However, no systematic study to 101 date has been conducted to assess its power. 102
Here, we established an analysis pipeline to systematically detect instances of i) aberrant 103 expression, ii) aberrant splicing, and iii) mono-allelic expression of the alternative allele to 104 complement whole exome sequencing based genetic diagnosis. We considered applying our 105 approach on patients diagnosed with a mitochondrial disorder for three reasons. First, 106
mitochondrial diseases collectively represent one of the most frequent inborn errors of 107 metabolism affecting 2 in 10,000 individuals 25 . Second, the broad range of unspecific clinical 108 symptoms and the genetic diversity in mitochondrial diseases makes molecular diagnosis 109 difficult and WES often results in variants of unknown significance. As a consequence of the bi-110 genomic control of the energy-generating oxidative phosphorylation (OXPHOS) system, 111 mitochondrial diseases may result from pathogenic mutations of the mitochondrial DNA 112 (mtDNA) or nuclear genome. More than 1,500 different nuclear genes encode mitochondrial 113 proteins 26 and causal defects have been identified in approximately 300 genes and presumably 114 more additional disease-associated genes still awaiting identification 27 . Third, since the diagnosis 115 often relies on biochemical testing of a tissue sample, fibroblast cell lines are usually available 116 from those patients. Moreover, for many patients, the disease mechanisms can be assayed in 117 epidermal fibroblast cell lines even though the disease may manifest in different tissues 28 . This 118 allows rapid demonstration of the necessary and sufficient role of candidate variants by 119 perturbation and complementation assays 29 . This also indicates that disease-causing expression 120
defects, if any, should be detectable in these cell lines. 121
Results 122 We performed RNA-seq on 105 fibroblast cell lines from patients with a suspected 123 mitochondrial disease including 48 patients for which whole exome sequencing based variant 124 prioritization did not yield a genetic diagnosis ( Fig. 1, Methods) . After discarding lowly 125 expressed genes, RNA-seq identified 12,680 transcribed genes (at least 10 reads in 5% of all 126 samples, Methods, Supplementary Data 1). We systematically prioritized genes with the 127 following three strategies: i) genes with aberrant expression level [11] [12] [13] , ii) genes with aberrant 128 splicing 22,30 , and iii) mono-allelic expression of rare variants 14 (Fig. 1) to estimate their disease 129 association. All strategies are based on the comparison of one patient against the rest. We 130 assumed the causal defects to differ between patients, which is reasonable for mitochondrial 131 disorders with a diversity of ~300 known disease-causing genes (Supplementary Data 2). 132
Therefore, the patients serve as good controls for each other. 133
Once normalized for technical biases, sex, and biopsy site (Supplementary information and 134 Supplementary Fig. 1 ), the samples typically presented few aberrantly expressed genes (median 135 of 1, Fig. 2a , Supplementary Table 1 ) with a large effect (|Z-score| > 3) and significant 136 differential expression (Hochberg adjusted P-value < 0.05). Among the most aberrantly 137 expressed genes across all samples, we found 2 genes encoding mitochondrial proteins, MGST1 138 (one case) and TIMMDC1 (two cases) to be significantly down-regulated ( Fig. 2b-d and 139 Supplementary Fig. 2 ). For both genes, WES did not identify any variants in the respective 140 patients, no variant is reported to be disease-associated, and no case of potential bi-allelic rare 141 variant is listed in our in-house database comprising more than 1,200 whole-exomes from 142 mitochondrial patients and 15,000 WES dataset available to us from different ongoing research 143 projects. To evaluate the consequences of diminished RNA expression at the protein level, we 144 performed quantitative proteomics in a total of 31 fibroblast cell lines (including these three 145 patients, and further 17 undiagnosed and 11 diagnosed patients, Methods, Supplementary Table  146 2, Supplementary Data 3) from a second aliquot of cells taken at the same time as the RNA-seq 147 aliquot. Normalized RNA and protein expression levels showed a median rank correlation of 148 0.59, comparable to what has been previously reported 31,32 ( Supplementary Fig. 3 ). Patient 149 #73804 showed ~2% of control MGST1 level whilst the lack of detection of TIMMDC1 in both 150 patients (#35791 and #66744) confirmed an even stronger effect on protein expression, 151
indicating loss of function ( Fig. 2e and Supplementary Fig. 4 ). MGST1, a microsomal 152 glutathione S-transferase, is involved in the oxidative stress defense 33 . Consequently, the loss of 153 expression of MGST1 is not only a likely cause of the disease of this patient, who suffers from 154 an infantile-onset neurodegenerative disorder similar to a recently published case with another 155 defect in the reactive oxygen species (ROS) defense system (Supplementary Information) 34 , but 156 also suggests a treatment with antioxidants. Both TIMMDC1 patients presented with muscular  157 hypotonia, developmental delay, and neurological deterioration, which led to death in the first 3 158
years of life (Supplementary Information). Consistent with the described function of TIMMDC1 159 as a respiratory chain complex I assembly factor 35,36 , we found isolated complex I deficiency in 160 muscle ( Supplementary Fig. 2 ), and globally decreased levels of complex I subunits in 161 fibroblasts by quantitative proteomics ( Fig. 2e and Supplementary Fig. 2 ) and western blot ( Fig.  162 2f). Re-expression of TIMMDC1 in these cells increased complex I subunit levels ( Fig. 2f ). 163
These results not only validate TIMMDC1-deficiency as disease causing but also provide 164 compelling evidence for an important function of TIMMDC1 in complex I assembly. 165 166 We identified aberrant splicing events by testing for differential splicing in each patient 167 against the others, using an annotation-free algorithm able to detect also novel splice sites 168 (Methods, median of 5 abnormal events per sample, Fig. 3a ). Among the 175 aberrant spliced 169 genes detected in the undiagnosed patients, the most abundant events were, apart from 170 differential expression of isoforms, exon skipping followed by the creation of new exons ( Fig.  171 3b). Two genes encoding mitochondrial proteins, TIMMDC1 and CLPP, which were among the 172 20 most significant genes, caught our attention ( Supplementary Table 3 ). Out of 136 exon-173 junction reads overlapping the acceptor site of CLPP exon 6 for patient #58955, 82 (percent 174 spliced in 37 Ψ = 60%) skipped exon 5, and 14 (Ψ =10%) showed a 3'-truncated exon 5, in 175 striking contrast to other samples (Fig. 3c ). The likely genetic cause of these two splice defects is 176 a rare homozygous variant in exon 5 of CLPP affecting the last nucleotide of exon 5 (c.661G>A, 177 p.Glu221Lys 1.2×10 !! frequency in the ExAC database 38 , Supplementary Fig. 5 ). Both detected 178 splice defects result in truncated CLPP and western blots corroborated the complete loss of full-179 length CLPP ( Supplementary Fig. 5 [45] [46] [47] [48] . We further discovered an additional family in our in-house 204 WGS database (consisting of 36 patients with a suspected mitochondrial disorder and 232 further 205 patients with unrelated diseases) carrying the same homozygous intronic variant. In this family 206 three affected siblings presented with similar clinical symptoms although without a diagnosis of 207 a mitochondrial disorder ( Fig. 3e , Supplementary Fig. 2 ). Two siblings died before the age of 10. 208
A younger brother (#96687), now 6 years of age, presented with muscle hypotonia, failure to 209 thrive and neurological impairment (Supplementary Information), similar to the patients 210 described above. Western blot analysis confirmed TIMMDC1-deficiency ( Fig. 2f ) and impaired 211 complex I assembly, which was restored after re-expression of TIMMDC1 (Fig. 2g ). The 212 discovery of the same intronic TIMMDC1 variant in three unrelated families from three different 213 ethnicities provides convincing evidence on the causality of this variant for the TIMMDC1 loss-214 of-function. 215
In almost all non-TIMMDC1-deficiency samples, we noticed a few split reads supporting 216 inclusion of the new exon ( Fig. 3d ), consistent with an earlier report that many cryptic splice 217 sites are not entirely repressed but active at low levels 49 . We set out to quantify this phenomenon 218 and to interrogate the frequency of private exons originating from weakly spliced exons, 219 independent of their possible association with disease. Consequently, we modeled the 220 distribution of Ψ for the 1,603,042 splicing events detected genome-wide in 105 samples as a 221 mixture of three components. The model classified splicing frequencies per splice site as strong 222 (20%, with Ψ > 5.3%), weak (16%, with 0.16% < Ψ < 5.3%), or background (64%, with Ψ < 223 0.16%, Methods, Fig. 3f and Supplementary Fig. 6 ). Strikingly, the majority (70%, 4.4-fold more 224 than by chance) of the 17 discovered private exons originated from weak splice sites (Fig. 3f  225 bottom). These data confirm that weakly spliced cryptic exons are loci more susceptible to turn 226
into strongly spliced sites than other intronic regions. These weak splicing events are usually 227 dismissed as 'noise' since they are only supported by few reads in a given sample. Our analysis 228
shows that they can be detected as accumulation points across multiple individuals. Hence, these 229 results suggest that the prioritization of deep intronic variants of unknown significances gained 230 through WGS could be improved by annotating weak splice sites and their resulting cryptic 231 exons. 232
As a third approach, we searched for mono-allelic expression (MAE) of rare variants. In 233 median per sample, 35,521 heterozygous SNVs were detected by WES, of which 7,622 were 234 sufficiently covered by RNA-seq to call MAE (more than 10 reads), 20 showed MAE (Hochberg 235 adjusted P-value < 0.05, allele frequency ≥ 0.8), of which 6 were rare variants (minor allele 236 frequency < 0.001, Methods, Fig. 4a ). Amongst the 18 rare mono-allelic expressed variants in 237 patient #80256 was a VUS in ALDH18A1 (c.1864C>T, p.Arg622Trp, Fig. 4b ), encoding an 238 enzyme involved in mitochondrial proline metabolism 50 . This VUS had been seen in WES 239
compound heterozygous with a nonsense variant (c.1988C>A, p.Ser663*, Fig. 4b and 240
Supplementary Fig. 7 ). Variants in ALDH18A1 had been reported to be associated with cutis laxa 241 III (OMIM #138250) 51,52 , yet the patient did not present cutis laxa. Because of this inconsistent 242 phenotype and the unknown significance of the non-synonymous variant, the variants in 243 ALDH18A1 were not regarded as disease causing. However, RNA-seq-based aberrant expression 244
( Supplementary Fig. 7 ) and mono-allelic expression analysis prioritized ALDH18A1 again. Our 245 systematically performed validation by quantitative proteomics revealed severe reduction down 246 to ~2% ALDH18A1 ( Fig. 4c ), indicating that the rare MAE variant affects translation or protein 247 stability. Metabolomics profile of blood plasma was in accordance with a defect in proline 248 metabolism ( Fig. 4d ) and the following changes in urea cycle. Patient fibroblasts showed a 249 growth defect that was rescued by supplementation of proline, validating impaired proline 250 metabolism as the underlying molecular cause ( Fig. 4e ). Our experimental evidence strongly 251 suggests that the two observed variants are causal. Moreover, a recent report 53 on ALDH18A1 252 patients extended the phenotypic spectrum to spastic paraplegia (OMIM #138250), which 253 resembles the symptoms of our patient (Supplementary information). 254
In another patient (#62346) we found borderline non-significant low expression of MCOLN1 255 with 10 of 11 reads expressing an intronic VUS (c.681-19A>C, Fig. 4f ). This intronic variant 256 was detected as part of a retained intron, which introduced a nonsense codon (p. 257
Lys227_Leu228ins16*, Fig. 4f and Supplementary Fig. 8 pipeline. This is expected, since missense variants more likely affect protein function rather than 305
RNA expression ( Supplementary table 4 ). 306
To our surprise, many newly diagnosed cases were caused by a defective splicing event, 307
which caused loss of function (Fig 5b) , confirming the increasing role of splicing defects in both 308
Mendelian 54,55 and common disorders 30 . In the case of TIMMDC1, the causal variant was 309 intronic, and thus not covered by WES. Even when detected by WGS, such deep intronic 310 variants are difficult to prioritize from the sequence information alone. Here, we showed that 311
RNA-seq of large cohorts can provide important information about intronic positions that are 312 particularly susceptible to affect splicing when mutated. We showed that private exons often 313 arise from loci with weak splicing of about 1%. This suggests that rare variants affecting such 314 cryptic splice sites are more likely to affect splicing and that these can be detected as positions 315
with low yet consistent splicing. We reason that analysis of a RNA-seq compendium of healthy 316
donors across multiple tissues such as GTEx 56 could provide tissue-specific maps of cryptic 317 splice sites useful for prioritizing intronic variants. 318
Genetic disorders typically show specificity to some tissues, some of which might not be 319 easily accessible for RNA-sequencing. It is therefore natural to question whether transcriptome 320 sequencing of an unaffected tissue can help diagnosis. Here, we performed RNA-seq on patient 321 derived dermal fibroblast cell lines. The fibroblast cell lines are the byproducts of muscle 322 biopsies routinely undertaken in the clinic to biochemically diagnose mitochondrial disorders 323 with enzymatic assays. By using fibroblast cell lines we overcome the limited accessibility of the 324 affected tissues, which in the case of mitochondrial disorders are often high energy demanding 325 tissues like brain, heart, skeletal muscle or liver. It turns out that many genes with a 326 mitochondrial function are expressed in most tissues 57 , including fibroblasts. Hence, extreme 327 regulatory defects such as loss of expression or aberrant splicing of genes encoding 328 mitochondrial proteins can be detected in fibroblasts, even though the physiological consequence 329 on fibroblasts might be negligible. This property might be true for other diseases: the tissue-330 specific physiological consequence of a variant does not necessarily stem from tissue-specific 331 expression of the gene harboring the variant. In many cases, tissue-specificity might be due to 332 environmental or cellular context, or from tissue-specific expression of further genes. Hence, 333
tissue-specificity does not preclude RNA-seq of unaffected tissues from revealing the causative 334 defect for a large number of patients. Moreover, non-affected tissues have the advantage that the 335 regulatory consequences on other genes are limited and therefore the causal defects are more 336 likely to stand out as outliers 58 . 337
Parallel to our effort, another study systematically investigated the usage of RNA-seq for 338 molecular diagnosis with a similar sample size, using muscle biopsies from rare neuromuscular 339 disease patients 55 . Analogously to our approach, not only exome sequencing-based VUS 340 candidates were validated, but also new disease-causing mechanisms identified using RNA-seq 341
data. Despite a few differences in the approach (expression outliers were not looked for, only 342 samples of the affected tissues were considered and using samples of healthy donors as controls), 343
the results are in line with ours whereby aberrant splicing also turns out to be a frequent disease-344 causing event. Moreover, the success rate was even higher (35%) confirming the relevance of 345 using RNA-seq for diagnosis of Mendelian disorders. 346
In conclusion, we predict that RNA sequencing will become an essential companion of genome 347 sequencing to address undiagnosed cases of genetic disease. 348
Methods

349
Exome sequencing 350 Exome sequencing was essentially performed as described previously 59 whereas in latter case we assume that the heterozygous variants are on different alleles 370 ( Supplementary Fig. 9 ). This filter is designed for a recessive type disease model and does not 371 account for a single heterozygous variant that could be disease-causing in a dominant way. 372
Variant of unknown significance
373 "A variation in a genetic sequence whose association with disease risk is unknown. samples was below 10 reads the gene was considered "not expressed" and discarded from later 405 analysis. 406
Computing RNA fold changes and differential expression 407 Before testing for differential expression between one patient of interest and all others, we 408 controlled for technical batch effect, sex, and biopsy site as inferred from the expression of hox 409 genes (Supplementary information, Supplementary Data 1). We modeled the RNA-seq read 410 counts !,! of gene i in sample j with a generalized linear model using the R/Bioconductor 411 DESeq2 package 68,69 : 412
Where NB is the negative binomial distribution; ! is a gene specific dispersion parameter; ! 413 is the size factor of sample j; ! ! is the intercept parameter for gene i. The value of x !,! !"#$%&%"# is 1 414 for all RNA samples j of the patient of interest, thereby allowing for biological replicates, and 0 415 otherwise. The resulting vector ! !"#$%&%"# represents the log 2 -fold changes for one patient against 416 all others. Z-scores were computed by dividing the fold changes by the standard deviation of the 417 normalized expression level of the respective gene. The P-values corresponding to the 418 ! !"#$%&%"# were corrected for multiple testing using the Hochberg family-wise error rate 419 method 70 . 420 421 The LeafCutter 71 software was utilized to detect aberrant splicing. Each patient was tested 422 against all others. To adjust LeafCutter to the rare disease setting, we modified the parameters to 423 detect rare clusters, capture local gene fusion events and to detect junctions unique to a patient 424 (minclureads=30; maxintronlen=500,000; mincluratio=1e-5, Supplementary Data 5) . 425 Furthermore, one sample was tested against all other samples (min_samples_per_group=1; 426 min_samples_per_intron=1). The resulting P-values were corrected for multiple testing using a 427
Detection of aberrant splicing
family-wise error rate approach 70 . 428
The significant splice events (Hochberg adjusted P-value < 0.05) detected in the undiagnosed 429 patients were visually classified as exon skipping, exon truncation, exon elongation, new exon, 430 complex splicing (any other splicing event or a combination of the aforementioned ones) and 431 false positives (n=73, Fig 3b) . However, due to LeafCutter's restriction to split reads it is 432 difficult to detect intron retention events, since in a perfect intron retention scenario no split-433 reads are present. 434
For further analysis, only reads spanning a splice junction, so called split reads, were 435 extracted with a mapping quality of greater than 10 to reduce the false positive rate due to 436 mapping issues. Each splice site was annotated as belonging to the start or end of a known exon 437 or to be entirely new. For the reference exon annotation the GENCODE release 24 based on 438
GRCh37 was used 72 . The percent spliced in (Ψ) values for the 3' and 5' sites were calculated as 439 described earlier 37 : 440 where c is the component index, s the number of annotated sites and BetaBin the beta-452 binomial distribution. Hence, the components were modeled to have the same parameters ! , ! 453 in all three groups but their mixing proportions !,! to be group-specific. Fitting was performed 454 using the expectation-maximization algorithm. For the initial step, the data points were classified 455 as background (ψ < 0.001), weak spliced (ψ < 0.1) and canonical (ψ >=0.1). After convergence of 456 the clustering the obtained parameters were used to estimate the probability for each junction 457 side to belong to a given class. 458 459 For mono-allelic expression analysis only heterozygous single nucleotide variants with only 460 one alternative allele detected from exome sequencing data were used. The same quality filters 461
Detection of mono-allelic expression
were used as mentioned in the exome sequencing part, but no frequency filter was applied. To 462 get allele counts from RNA sequencing for the remaining variants the function pileLettersAt 463 from the R/Bioconductor package GenomicAlignments 67 was used. The data was further filtered 464
for variants with coverage of at least 10 reads on the transcriptome. 465
The DESeq2 package 68,69 was applied on the final variant set to estimate the significance of 466 the allele-specific expression. Allele-specific expression was estimated on each heterozygous 467 variant independently of others (i.e. without phasing the variants). For each sample, a 468 generalized linear model was fitted with the contrast of the coverage of one allele against the 469 coverage of the other alleles (condition). Specifically, we modeled !,! the number of reads of 470 variant i in sample j as: 471
Where NB is the negative binomial distribution; the dispersion parameter was fixed for all 472 variants to = 0.05, which is approximately the average dispersion over all samples based on 473 the gene-wise analysis; ! is the size factor of each condition; ! ! is the intercept parameter for 474 variant i. The value of x !,! !"#$%&%"# is 1 for the alternative alleles and 0 otherwise. The resulting 475 ! !"#$%&%"# represents the log 2 -fold changes for the alternative allele against the reference allele. 476
The independent filtering by DESeq2 was disabled (independentFiltering=FALSE) to keep the 477 coverage outliers among the results. To classify a variant as mono-allelically expressed a cutoff 478 of ! !"#$%&%"# ≥ 2 was used, which corresponds to an allele frequency ≥ 0.8, and we filtered 479
Hochberg adjusted P-values to be smaller than 0.05. 480 481 We performed quantitative proteomics from a second aliquot of cells taken at the same time 482
Mass spectrometric sample preparation
as the RNA-seq aliquot. Mass spectrometric sample preparation was done as described earlier 73 . 483
Briefly, cells were lysed in SDC lysis buffer (1% sodium deoxycholate, 10 mM TCEP, 40 mM 484 CAA, 100 mM Tris pH 8.5), boiled for 10 min at 95ºC, sonicated and diluted 1:1 with water for 485
LysC and trypsin digestion. The dilution buffer contained appropriate amounts of proteolytic 486 enzyme to ensure a ratio of 1:50 (µg enzyme / µg protein Processing of proteome intensities 506 The LFQ intensities and gene names were extracted for 6,566 protein groups from the 507 MaxQuant output file proteinGroups.txt. For protein groups with more than one member, the 508 first member was chosen to represent the group as single protein with a distinct gene name 509
(similar to earlier studies 79 ). MaxLFQ intensities of 0 actually represent non-quantified peaks 510
and were therefore replaced with missing values (NA). The 10 samples that had a frequency of 511 missing values higher than 50% were considered bad quality and were discarded. Furthermore, 512
proteins were discarded because they had no gene name assigned (n=198), were not the most 513 abundant among their duplicates (n=295), were not expressed in any sample (n=93), because 514 their 95th percentile was not detected (n=549), which was also considered as not expressed, 515
analogously to RNA filtering. Finally, 5,431 proteins and 31 samples were considered for further 516 analysis (Supplementary Data 3). 517 518 Since the mass spectrometric measurements of all samples were done in a single run, no 519 technical artifacts could be found with a hierarchical clustering. Protein differential expression 520 for each patient compared to the others was tested using moderated T-test approach as 521 implemented in the R/Bioconductor limma package 80 . The transcriptome covariates for sex and 522
Computing protein fold changes and differential expression
HOX effects were used in the linear model for normalization. 523 544 Fresh fibroblast cell pellets were resuspended in PBS supplemented with 0.25 mM PMSF 545 and 10 U/mL DNAse I and solubilized using 2 mg digitonin/mg protein. The mixture was 546 incubated on ice for 15 min followed by addition of 1 mL PBS and subsequent centrifugation for 547 10 min at 10000 g and 4°C. The pellet was resuspended in 1x MB (750 mM ε-aminocaproic 548 acid, 50 mM bis-Tris, 0.5 mM EDTA, pH 7.0) and subjected to whole protein quantification. 549
Transduction and Transfection
Blue native PAGE (BN-PAGE)
Membrane proteins were solubilized at a protein concentration of 2 µg/µL using 0.5% (v/v) n-550 dodecyl-β-d-maltoside (DDM) for 1 h on ice and centrifuge for 30 min at 10000 g at 4°C. Proline supplementation growth assay 561 We modified a method established earlier 51 . For the comparative growth assay, equal number 562 of cells (n=250) from patient and control were seeded in 96-well plates and cultured in DMEM 563 containing 10% of either normal or dialyzed FBS. Medium with normal FBS contains small 564 molecules, whereas medium with dialyzed FBS is free of molecules with a molecular weight 565 smaller than 10,000 mw (Proline-free medium). To confirm the effect of Proline deprivation, 566 DMEM containing dialyzed FBS was supplemented with 100 µM L-Proline to rescue the growth 567 defect. After paraformaldehyde fixation, nuclei were stained with 4',6-diamidino-2-phenylindole 568 (DAPI) and cell number was determined using a Cytation3 automated plate reader (BioTek, 569 USA). 570 571 Intensity of hydroethidine (HEt) oxidation products as a measure of cellular ROS production 572 was quantified in living skin fibroblasts using epifluorescence microscopy as described 573
Cellular ROS production
previously 82 
